Biomea Fusion, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BMEA Nasdaq 2830 biomeafusion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biomea Fusion, Inc.

Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study - Oct 13th, 2026 7:02 pm
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist - Oct 13th, 2026 2:08 pm
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist - Oct 12th, 2026 2:30 pm
Biomea Fusion Announces Termination of Proposed Public Offering of Securities - Sep 23rd, 2026 5:03 am
Biomea Fusion Announces Proposed Public Offering of Securities - Sep 22nd, 2026 2:05 pm
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Sep 4th, 2026 7:55 am
Biomea Fusion to Participate in Upcoming Investor Conferences - Sep 3rd, 2026 6:00 am
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year? - Sep 1st, 2026 7:40 am
Sector Update: Healthcare Stocks Softer Late Afternoon - Aug 24th, 2026 1:47 pm
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes - Aug 24th, 2026 5:00 am
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks - Aug 22nd, 2026 12:05 pm
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - Aug 13th, 2026 5:00 am
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Aug 5th, 2026 2:05 pm
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - Jun 5th, 2026 5:32 pm
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Jun 3rd, 2026 6:00 am
Biomea Fusion to Participate at Upcoming Investor Conferences - May 12th, 2026 2:05 pm
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - May 11th, 2026 2:54 pm
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - May 5th, 2026 3:50 pm
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - May 5th, 2026 2:20 pm
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - Apr 28th, 2026 2:31 pm